HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway
HH1-1, a novel Galectin-3 inhibitor, exerts anti-pancreatic cancer activity by blocking Galectin-3/EGFR/AKT/FOXO3 signaling pathway
复制标题
HH1-1是一种新型Galectin-3抑制剂，通过阻断Galectin-3/EGFR/AKT/FOXO3信号通路发挥抗胰腺癌活性
DOI：
10.1016/j.carbpol.2018.10.008
复制
发表时间：
2019
影响因子：
11.2
通讯作者：
Ding Kan
中科院分区：
文献类型：
--
作者：
Yao Yanli;Zhou Lishuang;Liao Wenfeng;Chen Huanjun;Du Zhenyun;Shao Chenghao;Wang Peipei;Ding Kan
Pancreatic ductal adenocarcinoma is a highly malignant gastrointestinal tumor. Molecular targeting therapy for pancreatic cancer is still limited. High expressed Galectin-3 in pancreatic cancer is positively correlated with disease progression, indicating that Galectin-3 can be employed as a predictor of poor prognosis. From safflower, we isolated and purified a homogeneous polysaccharide, HH1-1, which could bind to and inhibit Galectin-3. HH1-1 could block the interaction between Galectin-3 and EGFR. Following HH1-1 treatment, the binding ability between EGFR and Galectin-3 was reduced by 245.28 folds. HH1-1 could suppress pancreatic cancer cell proliferation, arrest the cell cycle in S phase, induce cell apoptosis, inhibit angiogenesis and impede tumor cell migration and invasion. Moreover, HH1-1 affected the Galectin-3/EGFR/AKT/FOXO3 signaling pathway and possessed anti-pancreatic cancer activityin vitroandin vivo, especially in patient-derived xenografts. Further study suggested that HH1-1 had almost no toxicity bothin vitroandin vivo. This adds new evidence to suggest that HH1-1 could be a promising therapeutic agent and support the pursuit of the Galectin-3 as a target in pancreatic cancer treatment.
